PULMICORT FLEXHALER

PULMICORT FLEXHALER™ is designed to help facilitate drug delivery to the lungs

PULMICORT FLEXHALER - Device in use

New formulation

  • PULMICORT FLEXHALER™ is formulated with a micronized carrier to help provide dose consistency 4 [Ref 4: data on file, DA-PFH-03.]

Breath actuation

  • PULMICORT FLEXHALER™ requires minimal patient coordination, utilizing a breath-actuated delivery system that relies primarily on air flow
  • Inspiratory flow rate required for PULMICORT FLEXHALER™ is >30 L/min

Drug delivery

  • The force created by a patient’s inhalation helps separate the budesonide aggregate into fine particles, aiding the delivery of medicine to where it’s needed…your patient’s lungs

Three simple steps – TWIST, CLICK, INHALE

  1. Twist the grip
  2. Listen for the "click"
  3. Inhale deeply and forcefully

Indications and Important Safety Information for PULMICORT FLEXHALER™

  • PULMICORT FLEXHALER™ is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age or older
  • PULMICORT FLEXHALER™ is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm
  • Particular care is needed for patients who are transferred from systemically active corticosteroids to PULMICORT FLEXHALER™ because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids (see WARNINGS in full Prescribing Information)
  • Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles
  • It is possible that systemic corticosteroid effects such as hypercorticism, reduced bone mineral density, and adrenal suppression may appear in a small number of patients, particularly at higher doses
  • Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown
  • Rare instances of glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids
  • Common adverse events reported in clinical trials, regardless of relationship to treatment, include nasopharyngitis, nasal congestion, pharyngitis, allergic rhinitis, and viral upper respiratory tract infection

Please click here for full Prescribing Information for PULMICORT FLEXHALER™.